74 Percent EBITDA Improvement at Zeltia Group in 2010

Yondelis(R) sales increase by 70 percent

MADRID, February 24, 2011 - Zeltia Group's net revenues totalled 153.5 million euro in 2010, 24.4
percent more than in 2009 (123.4 million euro). This performance is primarily
attributable to a 70 percent increase in Yondelis(R) sales.

Net sales in the Biopharmaceutical business amounted to 79.4 million euro
in 2010 (51.1 million euro in 2009), of which 72.1 million correspond to
Yondelis(R) (43.8 million euro in 2009).

The Biopharmaceutical segment accounted for 52 percent of total Group
revenues in 2010, exceeding for the first time the contribution from the
Consumer Chemicals business (73.2 million euro in 2010, compared with 71.1
million euro in 2009).

EBITDA improved by 74 percent in 2010 to -3.9 million euro (-15.3 million
euro in 2009).

Net income attributable to the parent company rose 71 percent with
respect to 2009.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialised in
the development of marinebased drugs for use in oncology and central nervous
system illnesses. Grupo Zeltia consists mainly of the following companies:
PharmaMar, the world-leading biotechnology company in advancing cancer care
through the discovery and development of innovative marine-derived medicines;
Noscira, a biotech firm focused on discovering and developing new drugs
against Alzheimer's disease and other neurodegenerative diseases of the
central nervous system; Genomica, Spain's leading molecular diagnostics
company; Sylentis, dedicated to researching therapeutic applications of gene
silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two
highly profitable companies that are leaders in their respective market
segments.

This note is also available on the Zeltia web site: www.zeltia.com

Carlos Martinez de la Serna, +34-91-444-4500